Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Research backs BNP (B-type natriuretic peptide) for predicting CHF (congestive heart failure):

This article was originally published in Clinica

Executive Summary

A US study has provided further evidence to support the use B-type natriuretic peptide (BNP) as a marker for congestive heart failure (CHF). Of 325 patients who presented at an emergency department with dyspnoea (shortness of breath), those with BNP concentrations four times that of the normal level had a 51% chance of either being admitted to the hospital with CHF or dying within six months. The study, by Alan Maisel of the University of California, San Diego and colleagues, appears in the Annals of Emergency Medicine (February 6).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT064579

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel